Portal hypertension

Current Opinion in Gastroenterology

Volumn 21, Issue 3, 2005, Pages 313-322

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ascites; Encephalopathy; Portal hypertension; Spontaneous bacterial peritonitis; Variceal hemorrhage

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CONTRAST MEDIUM; CYCLOOXYGENASE 2 INHIBITOR; DIURETIC AGENT; GADOLINIUM; LACTITOL; LACTULOSE; MIDODRINE; NADOLOL; NITRATE; OCTREOTIDE; OFLOXACIN; PHOSPHODIESTERASE INHIBITOR; POLITEF; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SILDENAFIL; SIMVASTATIN; SPIRONOLACTONE; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYDROTHORAX; HYPONATREMIA; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; RISK FACTOR; SPLANCHNIC BLOOD FLOW; SYSTEMATIC REVIEW; VASCULAR RESISTANCE;

HUMANS; HYPERTENSION, PORTAL;

EID: 17844409850     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000158110.13722.e0     Document Type: Review

References (67)

1. Garcia-Pagan JC, Bosch J. The resistance of the cirrhotic liver: a new target for the treatment of portal hypertension: 1985. J Hepatol 2004; 40:887-890.
2. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126:749-755.
3. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18:353-372. Comprehensive review of bacterial translocation in the pathogenesis of bacterial infections and the hyperdynamic circulatory state of cirrhosis.
4. Colle I, De Vriese AS, Van Vlierberghe H, et al. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int 2004; 24:63-68.
5. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis: a study of 200 patients. J Hepatol 2004; 40:823-830.
6. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37:902-908.
7. Villanueva C, Lopez-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004; 40:757-765. Two interesting studies demonstrating the value of a hepatic venous pressure gradient favorable response in preventing the development of complications of cirrhosis and reducing mortality in cirrhosis.
8. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39:280-283. Describes the appropriate technique for determining the hepatic venous pressure gradient.
9. Annet L, Materne R, Danse E, et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003; 229:409-414.
10. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004; 39: 204-210.
11. D'Amico G, Morabito A. Noninvasive markers of esophageal varices: another round, not the last. Hepatology 2004; 39:30-34.
12. Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004; 59:333-338.
13. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40:65-72. Largest study comparing ligation compared with propranolol demonstrating equivalent efficacy in preventing first variceal hemorrhage with significant complications associated with ligation.
14. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127:476-484. First study that demonstrates that nonselective β-blockers can effectively prevent the growth of small varices.
15. Imperiale TF, Chalasani N, Klein RW. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis. Am J Gastroenterol 2003; 98:2742-2750.
16. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40:652-659.
17. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39:746-753. Another study supporting the use of short-term antibiotic prophylaxis in patients with cirrhosis with variceal hemorrhage.
18. Avgerinos A, Armonis A, Stefanidis G, et al. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology 2004; 39:1623-1630.
19. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127:1123-1130.
20. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793-801.
21. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003; 361:952-954.
22. Targownik LE, Spiegel BM, Dulai GS, et al. The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. Am J Gastroenterol 2004; 99:1306-1315.
23. Raines DL, Dupont AW, Arguedas MR. Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding. Aliment Pharmacol Ther 2004; 19:571-581.
24. Bellis L, Moitinho E, Abraldes JG, et al. Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction: transjugular intrahepatic portosystemic shunt. Gut 2003; 52:130-133.
25. Tripathi D, Lui HF, Helmy A, et al. Randomised controlled trial of long term portographic follow up versus variceal band ligation following transjugular intrahepatic portosystemic stent shunt for preventing oesophageal variceal rebleeding. Gut 2004; 53:431-437.
26. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126:469-475. First large randomized controlled trial of coated TIPS stents demonstrating that they are associated with a lower rate of shunt dysfunction and a tendency for lower encephalopathy.
27. Angermayr B, Cejna M, Koenig F, et al. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003; 38:1043-1050.
28. Angermayr B, Cejna M, Karnel F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52:879-885.
29. Ferral H, Gamboa P, Postoak DW, et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for endstage liver disease score. Radiology 2004; 231:231-236.
30. Merli M, Nicolini G, Angeloni S, et al. The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol 2004; 99:1959-1965.
31. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39:841-856. Updated AASLD treatment recommendations for cirrhotic ascites.
32. Saab S, Nieto J, Ly D et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2004; 3:CD004889.
33. Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40:629-635.
34. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40:484-488.
35. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802-810.
36. Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004; 20:271-279.
37. Liu LU, Haddadin HA, Bodian CA, et al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 2004; 126:142-148.
38. Arroyo V. Review article, hepatorenal syndrome-how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther 2004; 20(Suppl 3):49-54, discussion 55-6.
39. Guevara M, Abecasis R, Terg R. Effect of celecoxib on renal function in cirrhotic patients with ascites: a pilot study. Scand J Gastroenterol 2004; 39:385-386.
40. Guevara M, Fernandez-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 2004; 40:646-651.
41. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40:55-64. Compelling pilot study demonstrating that TIPS placement in patients with hepatorenal syndrome who have responded to vasoconstrictors plus albumin leads to a further improvement in renal function and sodium excretion.
42. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004; 40:140-146.
43. Garcia-Tsao G. Spontaneous bacterial peritonitis: a historical perspective. J Hepatol 2004; 41:522-527.
44. Albillos A, de la Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363:1608-1610.
45. Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39:484-491.
46. Frances R, Munoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53:860-864.
47. Such J, Hillebrand DJ, Guamer C, et al. Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2004; 16:571-577.
48. Fernandez J, Navasa M, Garcia-Pagan JC, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004; 41:384-390.
49. Luyer MD, Jacobs JA, Vreugdenhil AC, et al. Enteral administration of high-fat nutrition before and directly after hemorrhagic shock reduces endotoxemia and bacterial translocation. Ann Surg 2004; 239:257-264.
50. Luyer MD, Buurman WA, Hadfoune M, et al. Pretreatment with high-fat enteral nutrition reduces endotoxin and tumor necrosis factor-alpha and preserves gut barrier function early after hemorrhagic shock. Shock 2004; 21:65-71.
51. Ramirez MJ, Ibanez A, Navasa M, et al. High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. J Hepatol 2004; 40:424-430.
52. Ahl B, Weissenborn K, van den HJ, et al. Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatology 2004; 40:73-79.
53. Shawcross DL, Balata S, Olde Damink SW, et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Gastrointest Liver Physiol 2004; 287:G503-G509.
54. Restuccia T, Gomez-Anson B, Guevara M, et al. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 2004; 39:1613-1622.
55. Shawcross DL, Davies NA, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40:247-254. interesting study showing that infected patients with cirrhosis are susceptible to ammonia-induced abnormalities in neuropsychological tests.
56. Blei AT. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol 2004; 40:327-330.
57. Romero-Gomez M, Ramos-Guerrero R, Grande L, et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004; 41:49-54.
58. Ortiz M, Cordoba J, Alonso J, et al. Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital poriosystemic shunts. J Hepatol 2004; 40:552-557.
59. Weissenborn K, Heidenreich S, Giewekemeyer K, et al. Memory function in early hepatic encephalopathy. J Hepatol 2003; 39:320-325.
60. Wein C, Koch H, Popp B, et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39:739-745.
61. Mattarozzi K, Stracciari A, Vignatelli L, et al. Minimal hepatic encephalopathy: longitudinal effects of liver transplantation. Arch Neurol 2004; 61:242-247.
62. Mechtcheriakov S, Graziadei IW, Mattedi M, et al. Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transpl 2004; 10:77-83.
63. Rose C, Jalan R. Is minimal hepatic encephalopathy completely reversible following liver transplantation? Liver Transpl 2004; 10:84-87.
64. Liu Q, Duan ZP, Ha da K, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39:1441-1449. Provocative study demonstrating that modification of gut flora through probiotics and fiber improve not only encephalopathy but also liver function.
65. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328:1046.
66. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41:38-43. Important study demonstrating that a low-protein diet is not more effective than a normal diet in the resolution of episodic encephalopathy and could be detrimental.
67. Mullen KD, Dasarathy S. Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma? J Hepatol 2004; 41:147-148.